However, findings from large patient registries involving women exposed to GLP-1 RAs in early pregnancy for the treatment of type 2 diabetes or overweight/obesity are reassuring, suggesting no significant increase in adverse outcomes (79). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.